| 品牌 | 货号 | 产品规格 | 价格(RMB) | 库存（上海） | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
| 源叶(MedMol) | S82962-1mg | 99% | ￥125.00元 | 5 | - | - | - |
|
| 源叶(MedMol) | S82962-5mg | 99% | ￥230.00元 | 7 | - | - | - |
|
| 源叶(MedMol) | S82962-10mg | 99% | ￥420.00元 | 6 | - | - | - |
|
| 源叶(MedMol) | S82962-50mg | 99% | ￥1650.00元 | 3 | - | - | - |
|
| 源叶(MedMol) | S82962-100mg | 99% | ￥3200.00元 | 预计交期：2-3天 | - | - | - |
|
| 产品描述： Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment. | ||||||||||||||||||||
| 靶点： PI3Kδ:11 nM (IC50);PI3Kα:280 nM (IC50);PI3Kβ:480 nM (IC50);PI3Kγ:2.57 μM (IC50);DNA-PK:880 nM (IC50);DNA-PK; PI3K | ||||||||||||||||||||
|
体外研究： Expression of APDS mutant p110δ in cell lines and patient-derived lymphocytes lead to increased pathway activity, measured as phosphorylation of AKT or S6, which is suppressed by leniolisib in a concentration dependent way |
||||||||||||||||||||
|
体内研究： Oral leniolisib lead to a dose-dependent reduction in PI3K/AKT pathway activity and resolve the immune dysregulation with normalization of circulating transitional and naïve B cells and reduction in PD-1+CD4+ and senescent CD57+CD8+ T cells. After 12 weeks of treatment, all patients show amelioration of lymphoproliferation with lymph node sizes and spleen volumes reduced by 39% (mean, range 26-57%) and 40% (mean, range: 13-65%), respectively |
||||||||||||||||||||
|
参考文献： 1. Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406 |
||||||||||||||||||||
| 溶解性： Soluble in DMSO | ||||||||||||||||||||
| 保存条件： -20℃ | ||||||||||||||||||||
配置溶液浓度参考：
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
|---|
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京